Search

Highlights of Past EHA (HOPE) Latin America 2020

EHA and the Argentinian Society of Hematology (SAH) are very happy to announce that the Highlights of Past EHA (HOPE) Latin America 2020 will take place on November 13, 2020 in a virtual format.

Read more

Meet Eva Hellström-Lindberg, our Volunteer of the Month

Can you tell us what you do for EHA and when you started?
These days I am not as involved in EHA as I used to be, besides the various services when asked for, which I think is how it should…

Read more

Meet Eva Hellström-Lindberg, our Volunteer of the Month

Can you tell us what you do for EHA and when you started?
These days I am not as involved in EHA as I used to be, besides the various services when asked for, which I think is how it should…

Read more

EHA Mentorship Program

A new, career-focused program that provides individual mentoring support for early and mid-career clinicians and researchers in hematology. The call for mentees is open until 15:00 (CET) on February 20, 2025.

Read more

Pivotal Ruxolitinib Data Shows Promise for Patients with PV.

 

Polycythemia vera (PV) is a chronic, incurable blood cancer with limited treatment options. If uncontrolled, PV can cause serious cardiovascular complications, such as stroke and heart attack.

Read more

EU commissioner Tonio Borg: 'we will continue to improve the life of people suffering from Thalassaemia'

 

Today, May 8, is International Thalassemia Day. Today, we seek to enhance the awareness and knowledge of thalassemia and other hemoglobin disorders.

Read more

A new targeted combination therapy with potential to eliminate relapsed chronic lymphocytic leukemia

Patients with chronic lymphocytic leukemia (CLL) that has recurred or isn’t responding to standard treatment need new therapies. A new combination of two targeted therapies is showing potential to eliminate CLL in these circumstances.

Read more

Targeting the B-cell Receptor in Aggressive B-cell Lymphomas

In collaboration with Dr. Lou Staudt, Pharmacyclics and associate investigators, we performed a clinical trial of a very potent inhibitor of Bruton Tyrosine Kinase (BTK) called ibrutinib.

Read more